Skip to main content

Table 3 Changes in the laboratory data of the study group

From: NS34A resistance-associated substitutions in chronic hepatitis C in Upper Egypt and regression of liver fibrosis after direct-acting antiviral therapy

Variable ALT AST PLT Bilirubin Fib-4 APRI
Baseline 44.86 ± 21.34 51.41 ± 22.95 195 ± 68 0.93 ± 0.40 2.42 ± 1.69 0.821 ± 0.08
4 weeks 25.19 ± 9.07 32.46 ± 11.93 196 ± 66 1.29 ± 0.69   
 Percent of change − 43.84% − 36.86% 0.41% 38.7%   
p value 0.001*  0.001* ns 0.001*   
8 weeks 23.46 ± 9.33 27.64 ± 10.91 207 ± 74 1.26 ± 0.64   
 Percent of change − 47.70% − 46.23% 5.80% 35.48%   
p value 0.001*  0.001* ns 0.001*   
12 weeks (EOT) 26.68 ± 7.96 29.03 ± 7.14 215 ± 52 0.98 ± 0.44   
 Percent of change − 40.52% − 43.54% 10.11% 5.37%   
p value 0.001*  0.001*  0.05* ns   
12 weeks after EOT (SVR 12) 24.46 ± 7.63 29.53 ± 6.61 218 ± 64 0.77 ± 0.20 1.60 ± 0.61 0.407 ± 0.08
 Percent of change − 45.47% − 42.55% 11.67% − 17.2% − 33.88% − 50.42%
p value 0.001*  0.001*  0.05*  0.001* 0.001* 0.027*
  1. Data were expressed as mean ± standard deviation
  2. Percent of change = [(variable 12 weeks after EOT − variable at baseline)/variable at baseline] × 100
  3. All p values compared the changes in the mean value of each parameter at a certain time in relation to the baseline, *Highly statistical significance
  4. EOT endo of treatment, SVR12 sustained virological response with HCV RNA negative at 12 weeks after the end of therapy, ns not statistically significant